beta-1 receptor Inhibitors
1 drugsAbout beta-1 receptor
The beta-1 receptor (ADRB1) is a G protein-coupled receptor primarily found in the heart, regulating heart rate and contractility. Activation by catecholamines triggers a signaling cascade, increasing cardiac output. It is a significant target for drugs modulating cardiovascular function.
Currently, there is no genetic evidence data available linking ADRB1 variations to specific diseases. Despite the lack of genetic support, its physiological importance makes it a relevant target for therapeutic intervention.
One FDA-approved drug, DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, targets the beta-1 receptor. This drug, approved in 1983, is a small molecule used in an area classified as 'Other'.
Top beta-1 receptor Drugs
Pfizer is the top company with an approved drug targeting the beta-1 receptor.
Low competition suggests a potential market opportunity, but also indicates possible challenges in target validation.
beta-1 receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets beta-1 receptor, using small molecule modality.
The lack of diverse modalities indicates a whitespace opportunity for novel therapeutic approaches like antibodies or peptides.
beta-1 receptor Clinical Trials 27 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on beta-1 receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 5 | 1 | 0 | 83% |
| Phase 2 | 9 | 4 | 3 | 1 | 57% |
| Phase 3 | 4 | 2 | 1 | 1 | 67% |
| Phase 4 | 8 | 4 | 0 | 4 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
beta-1 receptor Drug Approval Timeline (1983 - 1983)
Shock
The first and most recent drug approval for the beta-1 receptor was in 1983.
The lack of recent approvals suggests potential saturation or challenges in developing new therapies for this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 22 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on beta-1 receptor. A trial counts if an approved drug acting on beta-1 receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.